SynthesisTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2014
Association between p53 codon 72 polymorphism and sarcoma risk among Caucasians.
Synthesis in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 5 citations in OpenAlex.
- Association Between TP53 Gene Codon 72 Polymorphism and Acute Myeloid Leukemia Susceptibility: Evidence Based on a Meta-Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2015Pooled it
- Evaluation of the p53 Arg72Pro polymorphism and its association with cancer risk: a HuGE review and meta-analysis.Genetics research · 2015Pooled it
- p53 p.Pro72Arg (rs1042522) and Mouse Double Minute 2 (MDM2) Single-Nucleotide Polymorphism (SNP) 309 Variants and Their Interaction in Chronic Lymphocytic Leukemia(CLL): A Survey in CLL Patients from Western Iran.International journal of hematology-oncology and stem cell research · 2021Article
- No association of TP53 codon 72 and intron 3 16-bp duplication polymorphisms with breast cancer risk in Chinese Han women: new evidence from a population-based case-control investigation.European journal of medical research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many published data on the association between p53 codon 72 polymorphism and sarcoma risk showed inconclusive results. The present study was designed to derive a more precise estimation of this connection among Caucasians. We conducted a literature search in PubMed, EMBASE, Web of Science, and CNKI databases for case-control studies examining the association between p53 codon 72 polymorphism and sarcoma risk. The meta-analysis was performed using STATA 12.0 software. Crude odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were used to measure the strength of any association. The results of this meta-analysis did not provide statistical evidence for significant sarcoma risk associated with p53 codon 72 polymorphism (OR(Arg/Arg vs. Pro/Pro) = 1.00, 95% CI = 0.80-1.26, P(heterogeneity) = 0.980; OR(Arg/Arg + Arg/Pro vs. Pro/Pro) = 0.99, 95% CI = 0.83-1.19, P(heterogeneity) = 0.990; OR(Arg/Arg vs. Arg/Pro + Pro/Pro) = 1.09, 95% CI = 0.89-1.35, P(heterogeneity) = 0.532; OR(allele Arg vs. allele Pro) = 1.03, 95% CI = 0.90-1.18, P(heterogeneity) = 0.883; OR(Arg/Pro vs. Pro/Pro) = 0.95, 95% CI = 0.71-1.27, P(heterogeneity) = 0.919). We also did not find significant links in further subgroup analyses by ethnicity, control source, and sarcoma type. The present meta-analysis of currently available data suggests that the p53 codon 72 polymorphism may not play a role in sarcoma development in Caucasians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.